MedTech Dive June 10, 2024
Abbott will launch two over-the-counter glucose monitors in the U.S., competing directly with Dexcom’s Stelo.
Dive Brief:
- Abbott said Monday it will launch two over-the-counter continuous glucose monitors after receiving clearance from the Food and Drug Administration.
- One product is the company’s Lingo device, sold as a wellness product for people who do not have diabetes. The other is Abbott’s new Libre Rio device, which is intended for adults with Type 2 diabetes who do not use insulin, posing a direct challenge to Dexcom’s Stelo device.
- After Lingo was cleared last week, RBC Capital Markets analyst Shagun Singh wrote the over-the-counter nod could offer a more than $1 billion sales opportunity for Abbott.
Dive Insight:
Abbott had...
Today's Sponsors
Today's Sponsor